Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung: Dezember 2000

U. Büttner; M. Chofflon; K. Hess; L. Kappos; J. Kesselring; H. P. Ludin; M. Schluep; C. Vaney; U. Baumhackl; T. Berger; F. Deisenhammer; M. Freimüller; H. P. Hartung; H. Kollegger; W. Kristoferitsch; H. Lassmann; H. Markut; K. Vass; H. Altenkirch; J. Boese; A. Gass; W. Gehlen; N. Goebels; J. Haas; G. Haferkamp; F. Heidenreich; R. Heitmann; B. Hemmer; R. Hohlfeld; R. W.C. Janzen; E. Jügelt; W. Kölmel; N. König; K. Lowitzsch; U. Manegold; A. Melms; J. Mertin; H. F. Petereit; M. Pette; D. Pöhlau; S. Poser; M. Sailer; S. Schmidt; G. Schock; M. Schulz; D. Seidel; N. Sommer; M. Stangel; E. Stark; G. Stoll; W. Weinrich; H. Wiethölter; U. K. Zettl; F. Zipp; R. Zschenderlein; A. Bayas; A. Chan; P. Flachenecker; R. Gold; O. Grauer; S. Jung; B. Kallmann; V. Leussink; M. Mäurer; P. Rieckmann; K. V. Toyka; F. X. Weilbach

doi:10.1007/s001150050729

Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung: Dezember 2000

Translated title of the contribution: Escalating immunomodulatory therapy of multiple sclerosis - 1. Supplement

U. Büttner, M. Chofflon, K. Hess, L. Kappos, J. Kesselring, H. P. Ludin, M. Schluep, C. Vaney, U. Baumhackl, T. Berger, F. Deisenhammer, M. Freimüller, H. P. Hartung, H. Kollegger, W. Kristoferitsch, H. Lassmann, H. Markut, K. Vass, H. Altenkirch, J. BoeseA. Gass, W. Gehlen, N. Goebels, J. Haas, G. Haferkamp, F. Heidenreich, R. Heitmann, B. Hemmer, R. Hohlfeld, R. W.C. Janzen, E. Jügelt, W. Kölmel, N. König, K. Lowitzsch, U. Manegold, A. Melms, J. Mertin, H. F. Petereit, M. Pette, D. Pöhlau, S. Poser, M. Sailer, S. Schmidt, G. Schock, M. Schulz, D. Seidel, N. Sommer, M. Stangel, E. Stark, G. Stoll, W. Weinrich, H. Wiethölter, U. K. Zettl, F. Zipp, R. Zschenderlein, A. Bayas, A. Chan, P. Flachenecker, R. Gold, O. Grauer, S. Jung, B. Kallmann, V. Leussink, M. Mäurer, P. Rieckmann, K. V. Toyka, F. X. Weilbach

University Hospital Würzburg

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

New clinical studies in multiple sclerosis provided data on the treatment of clinical isolated syndromes and secondary progressive forms which may have important implications for the optimal care of MS patients. The MSTKG critically evaluated the available data again and provides evidence-based recommendations for the application of immunoprophylactic therapies. Initiation of treatment after the first relapse may be indicated if there is clear evidence from MRI for subclinical dissemination of disease. Recent trials indicate that efficacy of therapy with IFN-is more likely with superimposed bouts or other indicators of inflammatory disease activity than without them in secondary progressive MS. If immunoprophylactic treatments is initiated with a provisional diagnosis of MS, confirmation of MS is essential. In long-term treated patients secondary treatment failure should be identified by follow-up examinations and other treatment options discussed.

Translated title of the contribution	Escalating immunomodulatory therapy of multiple sclerosis - 1. Supplement
Original language	German
Pages (from-to)	150-157
Number of pages	8
Journal	Nervenarzt
Volume	72
Issue number	2
DOIs	https://doi.org/10.1007/s001150050729
State	Published - 2001
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s001150050729

Cite this

Büttner, U., Chofflon, M., Hess, K., Kappos, L., Kesselring, J., Ludin, H. P., Schluep, M., Vaney, C., Baumhackl, U., Berger, T., Deisenhammer, F., Freimüller, M., Hartung, H. P., Kollegger, H., Kristoferitsch, W., Lassmann, H., Markut, H., Vass, K., Altenkirch, H., ... Weilbach, F. X. (2001). Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung: Dezember 2000. Nervenarzt, 72(2), 150-157. https://doi.org/10.1007/s001150050729

@article{79e1a29d8bba4ca3b0cb0448b4e3ba22,

title = "Immunmodulatorische stufentherapie der multiplen sklerose. 1. Erg{\"a}nzung: Dezember 2000",

abstract = "New clinical studies in multiple sclerosis provided data on the treatment of clinical isolated syndromes and secondary progressive forms which may have important implications for the optimal care of MS patients. The MSTKG critically evaluated the available data again and provides evidence-based recommendations for the application of immunoprophylactic therapies. Initiation of treatment after the first relapse may be indicated if there is clear evidence from MRI for subclinical dissemination of disease. Recent trials indicate that efficacy of therapy with IFN-is more likely with superimposed bouts or other indicators of inflammatory disease activity than without them in secondary progressive MS. If immunoprophylactic treatments is initiated with a provisional diagnosis of MS, confirmation of MS is essential. In long-term treated patients secondary treatment failure should be identified by follow-up examinations and other treatment options discussed.",

keywords = "Consensus, Immunomodulation, Multiple sclerosis, Therapy",

author = "U. B{\"u}ttner and M. Chofflon and K. Hess and L. Kappos and J. Kesselring and Ludin, {H. P.} and M. Schluep and C. Vaney and U. Baumhackl and T. Berger and F. Deisenhammer and M. Freim{\"u}ller and Hartung, {H. P.} and H. Kollegger and W. Kristoferitsch and H. Lassmann and H. Markut and K. Vass and H. Altenkirch and J. Boese and A. Gass and W. Gehlen and N. Goebels and J. Haas and G. Haferkamp and F. Heidenreich and R. Heitmann and B. Hemmer and R. Hohlfeld and Janzen, {R. W.C.} and E. J{\"u}gelt and W. K{\"o}lmel and N. K{\"o}nig and K. Lowitzsch and U. Manegold and A. Melms and J. Mertin and Petereit, {H. F.} and M. Pette and D. P{\"o}hlau and S. Poser and M. Sailer and S. Schmidt and G. Schock and M. Schulz and D. Seidel and N. Sommer and M. Stangel and E. Stark and G. Stoll and W. Weinrich and H. Wieth{\"o}lter and Zettl, {U. K.} and F. Zipp and R. Zschenderlein and A. Bayas and A. Chan and P. Flachenecker and R. Gold and O. Grauer and S. Jung and B. Kallmann and V. Leussink and M. M{\"a}urer and P. Rieckmann and Toyka, {K. V.} and Weilbach, {F. X.}",

year = "2001",

doi = "10.1007/s001150050729",

language = "Deutsch",

volume = "72",

pages = "150--157",

journal = "Nervenarzt",

issn = "0028-2804",

publisher = "Springer Verlag",

number = "2",

}

Büttner, U, Chofflon, M, Hess, K, Kappos, L, Kesselring, J, Ludin, HP, Schluep, M, Vaney, C, Baumhackl, U, Berger, T, Deisenhammer, F, Freimüller, M, Hartung, HP, Kollegger, H, Kristoferitsch, W, Lassmann, H, Markut, H, Vass, K, Altenkirch, H, Boese, J, Gass, A, Gehlen, W, Goebels, N, Haas, J, Haferkamp, G, Heidenreich, F, Heitmann, R, Hemmer, B, Hohlfeld, R, Janzen, RWC, Jügelt, E, Kölmel, W, König, N, Lowitzsch, K, Manegold, U, Melms, A, Mertin, J, Petereit, HF, Pette, M, Pöhlau, D, Poser, S, Sailer, M, Schmidt, S, Schock, G, Schulz, M, Seidel, D, Sommer, N, Stangel, M, Stark, E, Stoll, G, Weinrich, W, Wiethölter, H, Zettl, UK, Zipp, F, Zschenderlein, R, Bayas, A, Chan, A, Flachenecker, P, Gold, R, Grauer, O, Jung, S, Kallmann, B, Leussink, V, Mäurer, M, Rieckmann, P, Toyka, KV & Weilbach, FX 2001, 'Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung: Dezember 2000', Nervenarzt, vol. 72, no. 2, pp. 150-157. https://doi.org/10.1007/s001150050729

TY - JOUR

T1 - Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung

T2 - Dezember 2000

AU - Büttner, U.

AU - Chofflon, M.

AU - Hess, K.

AU - Kappos, L.

AU - Kesselring, J.

AU - Ludin, H. P.

AU - Schluep, M.

AU - Vaney, C.

AU - Baumhackl, U.

AU - Berger, T.

AU - Deisenhammer, F.

AU - Freimüller, M.

AU - Hartung, H. P.

AU - Kollegger, H.

AU - Kristoferitsch, W.

AU - Lassmann, H.

AU - Markut, H.

AU - Vass, K.

AU - Altenkirch, H.

AU - Boese, J.

AU - Gass, A.

AU - Gehlen, W.

AU - Goebels, N.

AU - Haas, J.

AU - Haferkamp, G.

AU - Heidenreich, F.

AU - Heitmann, R.

AU - Hemmer, B.

AU - Hohlfeld, R.

AU - Janzen, R. W.C.

AU - Jügelt, E.

AU - Kölmel, W.

AU - König, N.

AU - Lowitzsch, K.

AU - Manegold, U.

AU - Melms, A.

AU - Mertin, J.

AU - Petereit, H. F.

AU - Pette, M.

AU - Pöhlau, D.

AU - Poser, S.

AU - Sailer, M.

AU - Schmidt, S.

AU - Schock, G.

AU - Schulz, M.

AU - Seidel, D.

AU - Sommer, N.

AU - Stangel, M.

AU - Stark, E.

AU - Stoll, G.

AU - Weinrich, W.

AU - Wiethölter, H.

AU - Zettl, U. K.

AU - Zipp, F.

AU - Zschenderlein, R.

AU - Bayas, A.

AU - Chan, A.

AU - Flachenecker, P.

AU - Gold, R.

AU - Grauer, O.

AU - Jung, S.

AU - Kallmann, B.

AU - Leussink, V.

AU - Mäurer, M.

AU - Rieckmann, P.

AU - Toyka, K. V.

AU - Weilbach, F. X.

PY - 2001

Y1 - 2001

N2 - New clinical studies in multiple sclerosis provided data on the treatment of clinical isolated syndromes and secondary progressive forms which may have important implications for the optimal care of MS patients. The MSTKG critically evaluated the available data again and provides evidence-based recommendations for the application of immunoprophylactic therapies. Initiation of treatment after the first relapse may be indicated if there is clear evidence from MRI for subclinical dissemination of disease. Recent trials indicate that efficacy of therapy with IFN-is more likely with superimposed bouts or other indicators of inflammatory disease activity than without them in secondary progressive MS. If immunoprophylactic treatments is initiated with a provisional diagnosis of MS, confirmation of MS is essential. In long-term treated patients secondary treatment failure should be identified by follow-up examinations and other treatment options discussed.

AB - New clinical studies in multiple sclerosis provided data on the treatment of clinical isolated syndromes and secondary progressive forms which may have important implications for the optimal care of MS patients. The MSTKG critically evaluated the available data again and provides evidence-based recommendations for the application of immunoprophylactic therapies. Initiation of treatment after the first relapse may be indicated if there is clear evidence from MRI for subclinical dissemination of disease. Recent trials indicate that efficacy of therapy with IFN-is more likely with superimposed bouts or other indicators of inflammatory disease activity than without them in secondary progressive MS. If immunoprophylactic treatments is initiated with a provisional diagnosis of MS, confirmation of MS is essential. In long-term treated patients secondary treatment failure should be identified by follow-up examinations and other treatment options discussed.

KW - Consensus

KW - Immunomodulation

KW - Multiple sclerosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0035116740&partnerID=8YFLogxK

U2 - 10.1007/s001150050729

DO - 10.1007/s001150050729

M3 - Artikel

C2 - 11256151

AN - SCOPUS:0035116740

SN - 0028-2804

VL - 72

SP - 150

EP - 157

JO - Nervenarzt

JF - Nervenarzt

IS - 2

ER -

Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung: Dezember 2000

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this